AN ANALYSIS OF 42 WEGENERS GRANULOMATOSIS PATIENTS TREATED WITH METHOTREXATE AND PREDNISONE

被引：221

作者：

SNELLER, MC

HOFFMAN, GS

TALARWILLIAMS, C

KERR, GS

HALLAHAN, CW

FAUCI, AS

机构：

[1] Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland

[2] Cleveland Clinic Foundation, Cleveland, Ohio

[3] Veterans Affairs Medical Center, Washington, District of Columbia

来源：

ARTHRITIS AND RHEUMATISM | 1995年 / 38卷 / 05期

关键词：

D O I：

10.1002/art.1780380505

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective. To determine the efficacy of low-dose methotrexate (MTX) plus prednisone in the treatment of Wegener's granulomatosis (WG). Methods. An open-label study of weekly low-dose MTX plus prednisone for the treatment of WG was performed. Forty-two patients who did not have immediately life-threatening disease were enrolled into the study. Outcome was determined by clinical characteristics and pathologic, laboratory, and radiographic findings. Results. Weekly administration of MTX and prednisone resulted in remission of disease in 30 of the 42 patients (71%). The median time to remission was 4.2 months, The estimated median time to relapse for all patients in whom remission was achieved was 29 months. Eight patients who had relapses were treated with a second course of MTX plus prednisone, and a second remission was induced in 6 of the 8 (75%). Conclusion. Weekly low-dose MTX was shown in this study to be an acceptable alternative form of therapy for selected patients with WG who do not have immediately life-threatening disease or who have developed serious cyclophosphamide-associated toxicity.

引用

页码：608 / 613

页数：6

共 25 条

[1]

Fauci A, Wolff S, Wegener's granulomatosis: studies in eighteen patients and a review of the literature, Medicine (Baltimore), 52, pp. 535-561, (1973)

[2]

Fauci AS, Haynes BF, Katz P, Wolff SM, Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years, Ann Intern Med, 98, pp. 76-85, (1983)

[3]

Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS, Wegener granulomatosis: an analysis of 158 patients, Ann Intern Med, 116, pp. 488-494, (1992)

[4]

Hoffman GS, Leavitt RY, Kerr GS, Fauci AS, The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate, Arthritis Rheum, 35, pp. 1322-1329, (1992)

[5]

Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, Calabrese LH, Fries JF, Lie JT, Lightfoot RW, Masi AT, McShane DJ, Mills JA, Stevens MB, Wallace SL, Zvaifler NJ, The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis, Arthritis Rheum, 33, pp. 1101-1107, (1990)

[6]

Kaplan A, Meier P, Non‐parametric estimation from incomplete observations, Journal of the American Statistical Association, 53, pp. 457-481, (1958)

[7]

Kerr GS, Fleisher TA, Hallahan CW, Leavitt RY, Fauci AS, Hoffman GS, Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis, Arthritis Rheum, 36, pp. 365-371, (1993)

[8]

Shiroky JB, Frost A, Shelton JD, Haegert DG, Newkirk MM, Neville C, Complications of immunosuppression associated with weekly low dose methotrexate, J Rheumatol, 18, pp. 1172-1175, (1991)

[9]

Leff R, Case JP, McKenzie R, Rheumatoid arthritis, methotrexate therapy, and Pneumocystis carinii pneumonia (letter), Ann Intern Med, 112, (1990)

[10]

Altz SM, Kendall LJ, Stamm AM, Cryptococcosis associated with low‐dose methotrexate for arthritis, Am J Med, 83, pp. 179-181, (1987)

← 1 2 3 →